Enrollment

The Swedish BioFINDER study is prospectively including 350 patients since 2008 with parkinsonian symptoms, including de novo subjects, from the Neurology clinic at the Skåne University Hospital in Lund, Sweden.

Inclusion criteria

• Fulfills the criteria of Parkinson’s disease, Parkinson’s disease with dementia, progressive supranuclear palsy or multiple system atrophy. De novo patents with early parkinsonian symptoms are also included.

Exclusion criteria

• Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.
• Current significant alcohol or substance misuse

Examinations

• Clinical assessment
• Advanced MRI
• CSF and blood sampling
• Cognitive tests
• Cell models
• Scales of  motor symptoms and non-motor symptoms like fatigue, sleep assessment, gait and balance, depression, apathy.

Follow-up

For 6 years  ensure an accurate diagnosis of Parkinson’s disease or atypical parkinsonian disorders. Clinical and cognitive assessments are repeated ever 12 months and clinical, cognitive, neurological and psychiatric assessment, as well as CSF/blood sampling and MRI are repeated ever 24 months.